These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25255847)

  • 1. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Russo A; Ientile V; Sottosanti L; Pimpinella G; Conforti A; Moretti U; Caputi AP; Trifirò G
    Drug Saf; 2014 Nov; 37(11):961-70. PubMed ID: 25255847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
    Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
    Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.
    Aagaard L; Nielsen LH; Hansen EH
    Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
    Correia Pinheiro L; Giezen TJ; Wolff-Holz E; Weise M; Laslop A; Hidalgo-Simon A
    Clin Pharmacol Ther; 2021 Nov; 110(5):1311-1317. PubMed ID: 34472087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
    Aagaard L; Weber CB; Hansen EH
    Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
    Klein K; Hazell L; Stolk P; Shakir S
    Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.
    Lassanova M; Liskova S; Tisonova J; Fundarkova S; Lassan S
    Bratisl Lek Listy; 2021; 122(7):443-448. PubMed ID: 34161110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-related deaths: an analysis of the Italian spontaneous reporting database.
    Leone R; Sottosanti L; Luisa Iorio M; Santuccio C; Conforti A; Sabatini V; Moretti U; Venegoni M
    Drug Saf; 2008; 31(8):703-13. PubMed ID: 18636789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy.
    Leone R; Magro L; Moretti U; Cutroneo P; Moschini M; Motola D; Tuccori M; Conforti A
    Drug Saf; 2010 Aug; 33(8):667-75. PubMed ID: 20635825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
    Francescon S; Fornasier G; Baldo P
    Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
    Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System.
    Wang G; Wang J; Du R; Wang Y; Li Z
    Paediatr Drugs; 2024 Mar; 26(2):175-185. PubMed ID: 38153627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
    Felix T; Jordan JB; Akers C; Patel B; Drago D
    Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
    Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
    Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.